Jersey’s Medical-Cannabis Exports Are Now Overwhelmingly Europe-Facing

Europe took about 85 percent of Jersey’s disclosed 2025 flower exports

Jersey’s medical-cannabis export market is now plainly oriented toward Europe. Government records released in 2026 show the island exported 5,739.40 kilograms of medical-cannabis flower to Europe in 2025, compared with 1,047.05 kilograms to Great Britain and Northern Ireland. On those disclosed figures, Europe accounted for about 84.6 percent of Jersey’s 2025 flower-export volume.

That is news now because the numbers were not previously set out in a way that showed both scale and destination mix. A March 20, 2026 Freedom of Information release published annual export volumes by destination grouping for 2024 and 2025. A second release on May 8 added month-by-month figures for the second half of 2025. Together, those disclosures turn a lightly sketched export story into a measurable one.

The change is not marginal. Jersey’s flower exports to Europe were 1,919.80 kilograms in 2024. In 2025 they rose to 5,739.40 kilograms, almost exactly three times the previous year’s level. The Great Britain and Northern Ireland lane also grew, from 233.90 kilograms in 2024 to 1,047.05 kilograms in 2025, but it remained much smaller than the Europe trade.

Across the disclosed flower categories, Jersey exported 2,353.70 kilograms in 2024 and 6,786.45 kilograms in 2025. That is not just an increase in shipments. It is a clearer picture of where the market is. The island is not chiefly serving a nearby British market and occasionally reaching the continent. The public record now shows the reverse. Europe is the main destination.

That matters because destination mix says more than a headline export total. It shows which regulatory systems growers have learned to serve, where commercial relationships are being built, and which buyers are absorbing volume. For Jersey’s licensed producers, the evidence now points to a business model tied primarily to continental European demand.

The timing also matters because Jersey’s own government has already framed medicinal cannabis as an export sector, not a local policy experiment. The new disclosures therefore land against an existing industrial strategy. They do not announce a theory. They show trade moving through it.

Freedom of Information releases turn Jersey’s cannabis trade from anecdote into measured export flow

The important institutional change here is not a new law. It is new visibility. A Freedom of Information release is a public-record disclosure that forces government departments to provide information they do not routinely publish. In this case, the responses from Health and Care Jersey fill in two pieces that outsiders usually struggle to obtain in controlled industries: where product went and when it moved.

The March release gives annual export volumes for cannabis flower and oil by destination grouping. For flower, the key categories are Great Britain and Northern Ireland, Europe, and in 2024 an additional small “Other” category. The May release then adds a monthly view for the last six months of 2025. That second disclosure is valuable because annual totals can hide whether growth came from a steady operating rhythm or a few large consignments.

One figure from that monthly record stands out. Jersey exported 1,584.50 kilograms of flower in November 2025 alone. That does not tell the whole story of the second half, but it does show the island was capable of dispatching product at a scale large enough to matter within European medical supply chains. The export flow was not purely symbolic.

The records also help separate flower from oil. Both products appear in the annual disclosure, but flower is the load-bearing category for this story because it carries the clear scale signal. In simple terms, dried flower is where Jersey’s disclosed export footprint becomes visible in tonnes rather than small niche volumes.

There are still limits to what the public can see. The destination category “Europe” is broad. The records do not identify which countries within Europe received the shipments, which companies supplied them, which importers bought them, or what prices were achieved. They do not show how concentrated the trade is. A broad European total could represent a diversified customer base, or a small number of large contracts. Those are very different risk profiles.

Even so, the policy architecture around the sector is not hard to identify. Jersey issued its first commercial medicinal-cannabis cultivation licences years earlier, and the government’s export strategy later described medicinal cannabis as a strong export opportunity into Europe. That same strategy also said Jersey had issued five licences for commercial cultivation and identified France and Europe as strategic trade themes through 2026.

That point is worth sitting with. The island’s government is not merely allowing a few companies to ship product if they can find buyers. It has formally placed medicinal cannabis inside its export planning. In practice, that means the sector sits closer to a targeted trade line than to an incidental byproduct of licensing.

For a general reader, the significance is straightforward. Medical-cannabis exports are not like ordinary agricultural sales. They depend on licensed cultivation, controlled handling, export permissions, and matching import channels at the destination. When volumes rise in this kind of system, they usually reflect more than a bumper harvest. They reflect institutional readiness and commercial acceptance at both ends of the route.

A small island producer is becoming part of Europe’s medical flower supply chain

The wider industry consequence is that Jersey now looks less like a peripheral producer and more like a functioning input source for Europe’s medical cannabis market. It remains small in absolute geopolitical terms. But medical cannabis is not traded like wheat or cut flowers. Supply is narrower, compliance burdens are higher, and buyers often need repeatable quality from licensed facilities. In that environment, a few tonnes from a new, reliable origin can matter.

For Jersey operators, the disclosures sharpen the real commercial map. The domestic market is not the story. Nor, at this point, is Great Britain and Northern Ireland the principal outlet, despite clear growth there. The center of gravity is Europe. That affects how producers think about customer development, product specifications, transport planning, and the risk of relying on one regional demand pool.

For European buyers, Jersey’s rise adds another nearby supply option from the British Isles. That does not mean buyers will automatically switch or expand orders. It does mean the purchasing conversation has one more credible origin with public evidence of meaningful 2025 shipment volume. In medical supply chains, credibility often begins with proof that product actually moved in size through lawful channels.

For investors and other market watchers, the main gain is not excitement. It is resolution. Jersey’s medicinal-cannabis story has had strategic language around it for some time, but strategy pages do not prove throughput. The 2026 disclosures do. They show that licensed production on the island is not only permitted on paper but converted into outbound trade, and that the trade is heavily Europe-facing.

The late-2025 monthly data add an operational clue as well. A month such as November, with 1,584.50 kilograms of flower exported, suggests the business may be driven by substantial shipment lots rather than a perfectly even release schedule. That is normal in export sectors built around contract deliveries, customs documentation, and destination-side intake capacity. It also means monthly volatility should not be mistaken for market failure.

There is also a policy-reading consequence beyond Jersey itself. European medical cannabis markets are often discussed through the lens of the largest importers or the biggest producing countries. These numbers show that smaller jurisdictions can still become useful supply nodes if government licensing, cultivation buildout, and export strategy line up. Jersey is not becoming a mass-market consumer jurisdiction. It is positioning itself as a specialist production and export platform.

That distinction matters because it changes who is affected. Retail cannabis businesses are not the main audience for this development. Licensed cultivators, processors, exporters, wholesalers, and medical-market distributors are. So are policymakers in other small jurisdictions considering whether controlled cultivation can become an export industry rather than only a domestic health-policy issue.

It also changes how the island should be compared. Jersey is not competing with local adult-use retail systems. It is competing for a place in a regulated medical supply chain where consistency, compliance, and cross-border relationships matter more than storefront count or tourism demand.

The export numbers are strong, but the next test is consistency, not novelty

The evidence now supports a firmer conclusion than was possible before. Jersey has moved beyond the stage where medicinal cannabis can be described only as a strategic possibility. Public records show an operating export lane, and that lane is directed mainly at Europe.

The harder test begins there. A single strong year can establish relevance, but it does not by itself establish durability. The current disclosures do not show export value, contract length, customer concentration, country-level destinations inside Europe, or whether 2026 kept pace with late 2025. They also do not reveal margins, pricing pressure, or how much of the trade depends on a handful of counterparties. Those unknowns matter because medical supply chains reward repeatability more than headline bursts.

There is also a structural exposure in the success itself. If roughly 85 percent of disclosed 2025 flower volume went to Europe, then Europe is not just an opportunity for Jersey. It is the dependency. Any change in continental demand, import conditions, purchasing preferences, or competitive supply would be felt more sharply on the island than a simple total-export figure might suggest.

At the same time, the concentration has a positive reading. Producers usually do not reach that kind of regional weighting by accident. It often signals that the product has found a market where specifications, buyer relationships, and logistics are aligning. Jersey’s own export strategy, with its emphasis on Europe and France through 2026, now looks less aspirational and more descriptive of the trade that actually formed.

That is the practical point for operators and observers. The question is no longer whether Jersey can generate medical-cannabis exports at all. It can, and at a volume that is material for a small licensed producer. The more serious question is whether it can keep Europe as a dependable outlet while turning a few disclosed milestones into a stable export business.

A sector stops being a policy talking point when its volumes begin to define its geography. Jersey’s medicinal-cannabis sector has reached that threshold. The geography is now clear. Europe is where the market is.